Flubendazole is a benzimidazole derivative used as an anthelmintic. The drug has recently regained attention in oncology due to its promising anticancer effects mediated by diverse molecular mechanisms [1]. It has a poor aqueous solubility, which impairs its bioavailability. Cyclodextrins, especially randomly methylated β-cyclodextrin (RMβCD), are widely utilized to improve the unfavorable physicochemical and biopharmaceutical properties of drugs through inclusion complex formation [2].
This study aims to develop and characterize inclusion complexes of flubendazole with RMβCD and evaluate their influence on physicochemical behavior and anticancer potential. Complexes were obtained using the physical mixture and kneading method in various molar ratios. Physicochemical characterization of flubendazole and its complexes was performed by ATR-FTIR spectroscopy, and the biological activity was evaluated in vitro on human keratinocytes (HaCaT) and human malignant melanoma (A375). Viability was assessed using the Alamar Blue assay, while apoptotic changes were visualized via immunofluorescence staining.
The physicochemical characterization of inclusion complexes showed the entrapment of the active substance in the cyclodextrin’s cavity. Flubendazole exhibited dose-dependent cytotoxicity on A375 cells, which was attenuated after complexation with RMβCD. The complexes induced lower toxicity on HaCaT cells compared to the pure drug. These findings support the potential of flubendazole–RMβCD inclusion complexes as a formulation strategy for use in oncology.
Author Contributions
Conceptualization, R.P. and C.T.; methodology, R.P.; software, R.P.; validation, C.T. and C.Ș.; formal analysis, T.M. and R.P.; investigation, R.P.; resources, C.T.; data curation, R.P. and T.M.; writing—original draft preparation, R.P.; writing—review and editing, C.T.; visualization, C.Ș.; supervision, C.T. and C.Ș.; project administration, C.Ș.; funding acquisition, C.T. All authors have read and agreed to the published version of the manuscript.
Funding
We would like to acknowledge the “Victor Babes” University of Medicine and Pharmacy Timisoara for their support in covering the costs of publication for this research paper.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
The original contributions are included in the abstract, further inquiries can be directed to the corresponding author.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Xing, X.; Zhou, Z.; Peng, H.; Cheng, S. Anticancer role of flubendazole: Effects and molecular mechanisms (Review). Oncol. Lett. 2024, 28, 558. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Păduraru, D.N.; Niculescu, A.-G.; Bolocan, A.; Andronic, O.; Grumezescu, A.M.; Bîrlă, R. An Updated Overview of Cyclodextrin-Based Drug Delivery Systems for Cancer Therapy. Pharmaceutics 2022, 14, 1748. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).